Clinical Trials Browser

Has results × tafasitamab × Clear all

Leukemia, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT05222555 2026-01-16

MINDway

Phase 1/2 Active not recruiting

53 enrolled 14 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT04680052 2025-12-22

InMIND

Phase 3 Active not recruiting

654 enrolled 40 charts 1 FDA

Lymphoid

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT05788289 2025-05-25

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Phase 2 Terminated

4 enrolled 8 charts

Lymphoid

Lymphoma, Mantle-Cell

NCT04134936 2024-10-16

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Phase 1 Completed

66 enrolled 21 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT05328102 2024-04-30

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Phase 2 Terminated

3 enrolled 6 charts

Lymphoid

Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT01685008 2023-11-07

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

Phase 2 Completed

92 enrolled 37 charts

Lymphoid

Lymphoma, Non-Hodgkin

NCT02399085 2023-10-23

L-MIND

Phase 2 Completed

81 enrolled 23 charts 2 FDA

Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02639910 2021-12-20

COSMOS

Phase 2 Completed

24 enrolled 13 charts

LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01685021 2018-02-22

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)

Phase 2 Terminated

22 enrolled 12 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

topMIND

MINDway

InMIND

A Study of Tafasitamab and Lenalidomide in People With Mantle Cell Lymphoma

Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat Non-Hodgkin's Lymphoma (NHL)

L-MIND

COSMOS

Study of Fc-Optimized Anti-CD19 Antibody (MOR00208) to Treat B-cell Acute Lymphoblastic Leukemia(B-ALL)